FibroGen, Inc. — Q2 2016 Form 10-Q
Entity note: The supplied filing identifies the registrant as FibroGen, Inc., not Kyntra Bio, Inc. It covers the quarter and six months ended June 30, 2016; financial amounts below are in U.S. dollars unless stated otherwise.
Business context and reporting period
FibroGen is a clinical-stage biopharmaceutical company. Its lead candidate, roxadustat, was in Phase 3 development for anemia in chronic kidney disease (CKD); pamrevlumab was in Phase 2 development for several fibrosis-related and cancer indications. The company had no product sales; revenue was primarily from Astellas and AstraZeneca collaboration agreements.
Financial results and liquidity
| Metric | Q2 2016 | Q2 2015 | Six months 2016 | Six months 2015 |
|---|---|---|---|---|
| Revenue | $89.3m | $120.6m | $117.6m | $136.8m |
| Operating expenses | $62.8m | $61.2m | $117.8m | $122.3m |
| Operating income (loss) | $26.5m | $59.3m | $(0.3)m | $14.6m |
| Net income (loss) | $24.3m | $57.1m | $(3.5)m | $10.7m |
| Diluted earnings (loss) per share | $0.35 | $0.83 | $(0.06) | $0.15 |
| Operating cash flow | — | $27.4m | $58.9m |
Q2 operating margin was approximately 29.7% versus 49.2% a year earlier; the six-month operating margin was approximately negative 0.2% versus 10.7%. The filing does not present a conventional gross margin measure. Six-month cash flow from investing was $7.2m and from financing was $2.5m. Cash and cash equivalents rose to $190.4m from $153.3m at year-end 2015. Short- and long-term investments totaled $151.6m; accounts receivable were $18.1m. Together these three balances totaled $360.1m, excluding restricted cash.
At June 30, current assets were $252.3m and current liabilities $66.4m (current ratio approximately 3.8). Lease financing obligations totaled $97.4m long-term; product development obligations were $15.5m. The filing does not identify conventional borrowings as a material liability. Accumulated deficit was $411.6m.
Changes versus the prior comparable period
- Revenue fell 26% in Q2 and 14% for the first half, principally because AstraZeneca-related upfront and milestone revenue was lower than in 2015. Q2 2016 included a $62m AstraZeneca payment and a $10m Astellas milestone; Q2 2015 included $120m from AstraZeneca and a $15m milestone.
- Q2 operating expenses increased 3%, while first-half expenses declined 4%. Lower outside-services spending after FibroGen reached its $116.5m cap on initial non-China roxadustat development funding partly offset higher clinical, manufacturing, employee-related and stock-compensation costs.
- Q2 remained profitable but earnings declined substantially year over year. First-half results shifted from net income to a net loss.
- Six-month operating cash flow declined to $27.4m from $58.9m. The 2016 result included a $15.1m increase in deferred revenue; collaboration-payment and revenue-recognition timing affected working capital.
Outlook, management commentary and risks
- Management expected existing cash, investments and receivables to fund anticipated needs for at least 12 months, while also stating that substantial additional funding would be needed in connection with continuing operations and that losses were expected for the foreseeable future. No formal revenue or earnings guidance was provided.
- FibroGen anticipated a U.S. roxadustat NDA filing in 2018. It expected to complete additional enrollment in a non-dialysis Phase 3 study by year-end 2016 and initial target enrollment in an incident-dialysis study in Q3 2016. China Phase 3 top-line data were expected by year-end 2016, with the company anticipating a China NDA process in Q4 2016 and a possible approval decision in the first half of 2018. These were forward-looking expectations, not assured outcomes.
- For pamrevlumab, enrollment in the controlled IPF Phase 2 study was complete; top-line data were expected in mid-2017. The company also described ongoing pancreatic cancer and DMD studies and anticipated further enrollment milestones.
- Development and commercialization of roxadustat depended significantly on Astellas and AstraZeneca, including continued collaboration, clinical execution, regulatory outcomes and partner funding. China development costs were shared equally; non-China CKD anemia development costs beyond the initial funding cap were to be borne by the partners.
- Key risks include Phase 3 safety and efficacy uncertainty, enrollment and manufacturing delays, regulatory uncertainty (particularly the relatively novel China pathway), future financing needs, competition, and reliance on collaboration partners. The filing highlighted potential roxadustat safety issues including cardiovascular endpoints and interactions with certain statins.
- GlaxoSmithKline filed inter partes review petitions challenging six FibroGen U.S. patents. FibroGen said the outcome was unpredictable and stated that even full revocation would not, in its view, eliminate roxadustat exclusivity or freedom to operate. A European patent covering anemia treatment with roxadustat had been revoked in opposition proceedings; FibroGen appealed and reported the patent remained valid and enforceable pending appeal.
- Management reported effective disclosure controls as of June 30, 2016 and no material change in internal control over financial reporting during the quarter. The company reported no material legal proceedings and no material changes to contractual obligations.
Important facts for investors to verify
- Confirm the issuer identity: this is a FibroGen, Inc. filing, not a Kyntra Bio, Inc. filing.
- Check the timing and conditions of collaboration receipts and milestone recognition, including the $62m AstraZeneca payment and the $10m Astellas milestone received in July.
- Track roxadustat trial enrollment, safety/event rates, regulatory discussions and the stated U.S. and China filing timelines.
- Assess the cash runway against ongoing losses, planned clinical spending, China cost-sharing and potential financing needs.
- Monitor the GSK patent challenges and European patent appeal, as well as partner commitment and manufacturing capacity.